Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths [Seeking Alpha]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Seeking Alpha
Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA's Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY's dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Miladin Pusicic/iStock via Getty Images Oncolytics Biotech Inc. ( ONCY ) is a clinical-stage biotechnology company focused on building a platform around its asset called Pelareorep (Pela). This is essentially a reovirus for the treatment of gastrointestinal cancers such as anal, colorectal, and pancreatic By concentrating resources on mCRC and SCAC, ONCY clarifies its bull case, increasing the likelihood of near-t
Show less
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyGlobeNewswire
- Oncolytics Biotech (ONCY) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (e+)".MarketBeat
- Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerGlobeNewswire
- Oncolytics Biotech (ONCY) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ONCY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "stronMarketBeat
- Oncolytics Biotech's Nevada Move Resets Capital Access And Dilution Trade Off [Yahoo! Finance]Yahoo! Finance
ONCY
Earnings
- 3/30/26 - Miss
ONCY
Sec Filings
- 4/27/26 - Form 8-K
- 4/8/26 - Form F-10POS
- 4/8/26 - Form F-10POS
- ONCY's page on the SEC website